Uncategorized

Mature biopharma deals are stealing all the headlines, but Bristol Myers Squibb’s Robert Plenge says the company’s deals with insitro, Orbital and more are building the future.

Staffers for Sen. Chuck Grassley, R-Iowa, dove into 50,000 pages of documentation from UnitedHealth for the new report, which accuses the company of maintaining a workforce dedicated to upcoding.

The deal would set up Boston Scientific to compete directly with Medtronic in the market for neuromodulation devices that work by stimulating the tibial nerve.

The physician lobby surveyed 64 medical societies and found that most of them were worried about nurses, physician assistants and other practitioners getting more freedom to provide care this year.

Edwards terminated the deal after the Federal Trade Commission moved to block the acquisition due to anticompetitive concerns.

Transactions involving providers and related services increased 57% year over year, spurred by healthcare IT deals, according to Bain & Company.

The company unveiled the appointment alongside news of the departure of its chief commercial officer.

While Moderna’s full-year sales landed in the upper end of its target range, Jefferies analysts said further reductions are needed if the biotech hopes to hit its 2028 break-even target.

The deal, which sees AbbVie paying RemeGen $650 million upfront, gives the pharma ex-China rights to the biotech’s PD-1/VEGF bispecific antibody—a modality being targeted by companies including BMS, Merck and Pfizer.

Cuando una célula muere, el organismo se deshace de ella para evitar su acumulación en los tejidos, lo que puede dar lugar a procesos inflamatorios en el intestino o el pulmón, entre otros. Las investigaciones sobre este proceso en cultivos celulares sugerían que la c&eac …